Article citationsMore>>

Colodny, L., Lynch, K., Farber, C., Papish, S., Phillips, K., Sanchez, M., Cooper, K., Pickus, O., Palmer, D., Percy, T.B., Faroqui, M. and Block, J.B. (2000) Results of a Study to Evaluate the Use of Propax to Reduce Adverse Effects of Chemotherapy. Journal of the American Nutraceutical Association, 3, 17-25.

has been cited by the following article:

• TITLE: Reduction of Pain, Fatigue, Gastrointestinal and Other Symptoms and Improvement in Quality of Life Indicators in Fibromyalgia Patients with Membrane Lipid Replacement Glycerolphospholipids and Controlled-Release Caffeine

  AUTHORS: Garth L. Nicolson, Robert Settineri, Gonzalo Ferreira, Paul Breeding

  KEYWORDS: Pain, Fatigue, Gastrointestinal Symptoms, Quality of Life, Phospholipids, Caffeine

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.9 No.7, July 26, 2018

  ABSTRACT: Objectives: A preliminary, open label study was initiated to determine if oral wafers containing a combination of membrane glycerolphospholipids and controlled-release caffeine could reduce self-reported pain, fatigue, and gastrointestinal symptoms and improve quality of life (QOL) indicators in fibromyalgia patients. Methods: Pain, fatigue and other symptoms were determined using validated, patient survey forms completed over an 8-day test period and compared to baseline values. Participants included 21 patients (15 females and 6 males) of average age of 48.5 ± 9.8 years with a diagnosis of fibromyalgia. These patients consumed four daily chewable wafers containing glycerolphospholipids (4.8 g) and one controlled-released caffeine (184 mg) wafer that maintained caffeine levels at approximately one cup of coffee for over 8 h. Results: Participants in the study responded to the combination test supplement within days. By the end of the study there were significant overall improvements (36.1%, p p p p p Conclusions: The combination membrane lipid replacement glycerolphospholipid supplement with controlled-release caffeine was safe and effective and significantly reduced pain, fatigue and gastrointestinal symptoms as well as improved QOL indicators in fibromyalgia patients.